Welcome to our dedicated page for SAB Biotherapeutics SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
SAB Biotherapeutics, Inc. filed a Form S-8 registration statement to register 24,180,000 additional shares of common stock for issuance under its 2021 Omnibus Equity Incentive Plan, as amended.
The registration covers the same class of securities as earlier S-8 statements and incorporates the company’s latest annual, quarterly, and current reports by reference, so the equity compensation plan remains supplied with stock for future grants to eligible participants.
SAB Biotherapeutics, Inc. reported an insider equity transaction by its Chief Medical Officer, Alexandra Kropotova. On 12/11/2025, 988 shares of common stock were withheld to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs).
After this transaction, Kropotova beneficially owned a total of 44,284 shares of common stock. This amount includes 31,946 shares of common stock and 12,338 shares that remain subject to vesting of RSUs granted under the company’s 2021 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock.
SAB Biotherapeutics, Inc. reported Q3 results showing a swing to net income, driven by non‑cash warrant valuation effects and a mid‑year capital raise. For the quarter, the company recorded net income of $45.4 million, while operating activities remained in investment mode with loss from operations of $12.7 million as R&D and G&A totaled $12.7 million. No revenue was recognized in the period.
The balance sheet strengthened markedly. As of September 30, 2025, cash and cash equivalents were $29.4 million, with short‑term investments of $81.5 million and long‑term investments of $50.6 million. Total assets rose to $183.4 million and stockholders’ equity to $165.1 million, reflecting proceeds from the 2025 private placement and equity reclassifications. The quarter included a $61.6 million gain from changes in fair value of warrant liabilities and $4.9 million of warrant issuance costs.
Year to date, net cash used in operations was $28.0 million, offset by $168.7 million provided by financing activities from the 2025 PIPE. The company noted existing resources are sufficient to cover operating cash needs for the twelve months following the report date. Common shares outstanding were 47,606,851 as of November 10, 2025.
SAB Biotherapeutics filed a prospectus supplement for a resale registration covering up to 250,000,000 shares of common stock to be offered by selling stockholders. The Resale Shares consist of common stock issuable upon conversion of Series B Convertible Preferred Stock and upon exercise of related Series B preferred stock purchase warrants that yield additional Series B shares for conversion.
This supplement states it is solely to update a footnote in the selling stockholders table. The selling stockholder list includes large allocations, including SESSA CAPITAL (MASTER) L.P. 57,125,000 and RA Capital Healthcare Fund, L.P. 42,850,000. Several holders are subject to beneficial ownership limits of 4.99% or 9.99% that cap conversions. The company’s common stock trades on Nasdaq as SABS; on November 5, 2025, the closing price was $3.18. The Series B Preferred Stock is not listed and is not intended to be listed.
SAB Biotherapeutics, Inc. Schedule 13G filings show affiliated Vivo Opportunity entities report beneficial ownership tied to convertible Series B Preferred Stock, Enrollment Warrants and Data Release Warrants. On September 29, 2025 4,401,500 shares of Common Stock were converted automatically from Series B Preferred Stock (4,000,000 and 401,500 shares by two Vivo groups). The filings report an aggregate of 25,931,000 shares attributable to Vivo Opportunity Fund Holdings/manager entities and 2,619,000 shares attributable to Vivo Opportunity Cayman entities, each disclosed as representing 9.99% of the class. Many additional shares are reported as issuable upon conversion/exercise within 60 days, but the securities include blocking provisions that prevent conversion or exercise that would raise ownership above 9.99%. Signatures show the filings were executed by Kevin Dai on October 3, 2025.
RA Capital and affiliated persons report owning 4,401,500 shares of SAB Biotherapeutics common stock, representing 9.99% of the outstanding shares following an automatic conversion tied to a private placement.
The position arose from the Fund's purchase of 171,400 Series B Preferred Shares on July 22, 2025 at $175 per share (aggregate $29,995,000). Upon stockholder approval at a special meeting, 44,015 Preferred Shares converted into 4,401,500 common shares. The Preferred Stock includes a Beneficial Ownership Blocker preventing conversion above 9.99% (adjustable up to 19.99% with 61 days' notice).
Commodore Capital LP and related filers report beneficial ownership of 4,522,977 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the outstanding class based on 45,108,294 shares reported by the issuer. The position includes 4,401,500 shares issued to Commodore Capital Master LP upon conversion of Series B Convertible Preferred Stock after stockholder approval on September 26, 2025, plus 121,477 additional shares issuable upon conversion but subject to a 9.99% ownership limitation (the "Ownership Blocker"). The filing discloses that larger pools of shares issuable on conversion and under warrants are excluded from the reported aggregate because they are constrained by the Ownership Blocker. Voting and dispositive power over the reported shares is shared among the filers; no filer reports sole voting or dispositive power.
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Sessa Capital reported the automatic conversion of Series B Convertible Preferred Stock into common stock of SAB Biotherapeutics (SABS) on 09/29/2025. The filing shows the Fund received 1,740,000 common shares as a result of converting 17,400 preferred shares at an effective price of $1.75 per share. The Fund originally acquired the preferred shares for an aggregate purchase price of $39,987,500 under a July 21, 2025 purchase agreement. After the conversion, the reporting persons collectively beneficially owned 2,198,457 shares of common stock. The conversion is subject to a 4.99% beneficial ownership limitation that restricts further conversions that would exceed that threshold.
SAB Biotherapeutics, Inc. reported that on September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from its Board of Directors. Their departures were made in line with a letter agreement between the company and RA Capital Healthcare Fund, L.P. related to a July 2025 private placement of securities. Following these resignations, the Board size was reduced from 11 to nine members. The company stated that the resignations were not due to any disagreement regarding its operations, policies, or practices and expressed appreciation for both directors’ service.